

## REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Claims 1, 3 and 4 have been amended so as to be dependent upon method claim 5.

Claim 5 has been amended to remove the "prevention" language and to limit the organs to those disclosed on page 302 of the specification. Please see line 9.

Claim 7 has been rewritten in conformance with U.S. practice. Support for the pharmaceutically acceptable carrier, excipient, binder or diluent is found in the specification at page 301, lines 10-11.

New claims 11-12 have been added for additional patent protection. This compound is the fourth compound listed in claim 3 and is also the elected species compound.

Turning to the Official Action, the Abstract was objected to on the basis of minor informalities. A new Abstract has been presented with this response in conformance with U.S. practice.

Claim 7 was rejected under 35 USC 101.

This ground of rejection is deemed to be overcome in view of the foregoing amendments to claim 7.

Claim 5 was rejected under 35 USC 112, first paragraph.

The rejection of claim 5 is deemed to be overcome in view of the foregoing amendments to claim 5.

Lastly, claims 1-4 and 9-10 were rejected under 35 USC 102(e) as anticipated by U.S. Patent No. 6,562,978. This ground of rejection is respectfully traversed as applied to the amended claims.

The cited reference fails to disclose or suggest the use of the claimed compounds in the method of claim 5. Specifically, the cited reference fails to disclose or suggest the use of a compound having a CCR antagonistic effect, or a salt thereof, for treating graft-versus host disease and/or rejection reactions during heart, kidney, liver or bone marrow transplantation.

In view of the foregoing, it is respectfully submitted that each ground of rejection and objection set forth in the Official Action has been overcome, and that the application is now in condition for allowance. Accordingly, such allowance is solicited.

Respectfully submitted,

Noboru TSUCHIMORI et al.

By: Warren M. Cheek  
Warren M. Cheek  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 23, 2008